



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant(s): Paul Young

Serial No: 09/954,456

Art Unit: 1631

Filed: 18 September 2001

Examiner: C. L. Smith

Title: PROCESS FOR IDENTIFYING ANTI-CANCER THERAPEUTIC AGENTS USING CANCER GENE SETS

Docket No: 669290-76

#7  
Plunkett  
S 15/03

7 May 2003

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**RECEIVED**

**ELECTION OF INVENTION**

MAY 12 2003

Sir:

TECH CENTER 1600/2900

In response to the Office Action, dated 27 January 2003, Applicants respond by electing the claims of Group I (claims 1-17) drawn to a process for screening for agents having cancer-gene related modulating activity with traverse.

Applicants believe that the claims of Group VI (claims 31-35 and 37-42), drawn to a method of treating cancer or protecting from cancer, should be combined with Group I for examination with the claims limited to use of compounds having activity in the screening claims.

The Office Action notes that each group also requires election of a particular sequence for examination. Applicant notes that, in speaking with the Examiner, it was agreed that in this line of cases (beginning with Application Serial No. 09/873,367) Applicant would elect 10 gene sequences and amend claim 1 to require a determination of modulation of more than one gene. This is accomplished in the accompanying Preliminary Amendment.

Applicant has therefore selected 10 sequences denoted in the application as SEQ ID NO: 851, 995, 1021, 1062, 1300, 1340, 1483, 1549, 1979 and 2032. The selection of these sequences is made clearer by reference to the accompanying Preliminary Amendment.

The GenBank accession numbers for these sequences are: 851 (AA432248), 995 (H18957), 1021 (AA251010), 1062 (N71027), 1300 (AA410986), 1340 (AA620885), 1483 (N52026), 1549 (H98215), 1979 (T87560) and 2032 (AA432292). These Accession Numbers were reported in the Figures accompanying the priority provisional applications on which the present case is based, the disclosures of which were incorporated by reference in their entirety, and are presented here only to facilitate the Examiner's search.

Applicants have also amended some claims in accordance with previous discussions with the Examiner's as well as to remove certain improper multiple claim dependencies. In addition, Applicants have amended claim 1 and others to better reflect the nature of the invention. Such amendments are contained in the accompanying Preliminary Amendment.

Applicant includes herewith a request for a 3 month extension of time to respond plus a check to cover the fee. The Commissioner is authorized to charge payment of any additional filing fees required under 37 CFR 1.16 associated with this communication or credit any overpayment to Deposit Account No. 03-0678.

FIRST CLASS CERTIFICATE

I hereby certify that this correspondence is being deposited today with the U.S. Postal Service as First Class Mail in an envelope addressed to:

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

*Alan J. Grant* 5/7/03  
Alan J. Grant, Esq. Date

Respectfully submitted,

*Alan J. Grant*

Alan J. Grant, Esq.  
Reg. No. 33,389

CARELLA, BYRNE BAIN, GILFILLAN,  
CECCHI, STEWART & OLSTEIN  
Six Becker Farm Road  
Roseland, NJ 07068  
Phone: 973-994-1700  
Fax: 973-994-1744